Leveraging AI and image analysis technology to improve prognostication in colorectal cancer

Korsuk Sirinukunwattana completed a PhD degree in Computer Science from the University of Warwick, focusing on computational pathology. He then became a postdoctoral research fellow at Beth Israel Deaconess Hospital, Harvard Medical School and is currently a postdoctoral research assistant at the University of Oxford, based at the Big Data Institute.

Korsuk’s research concerns leveraging artificial intelligence and image analysis technologies for the development of novel biomarkers extracted from histological slides with molecular and biological interpretability has remarkable potential for clinical translation. Using deep learning, he has predicted consensus molecular subtypes (CMS) of colorectal cancer (CRC) from standard histology sections.

The current standard for prognostication of CRC patients is based on the assessment of histologic materials and tumour progression as defined by the anatomical criteria (TNM staging system). This information supports the definition of broad prognostic risk groups but has no predictive value. The integration of genomic technologies in the clinical care of CRC patients has immense potential to drive personalised treatment but requires substantial financial, personnel and infrastructural resources. On the other hand, histology slides are generated as part of the standard work-up of any CRC treated by surgical resection. Combining morphological information derived from histology slides with molecular profiles to identify genotype-phenotype correlations is a promising and cost-effective approach to extend the amount of clinically relevant information that can be extracted from standard histologic slides.

In Oxford Korsuk collaborates with Jens Rittscher (IBME), and Enric Domingo and Tim Maughan (Oncology) as part of the S:CORT consortium. Internationally, he works with Viktor Koezler at the University of Zurich. He is funded by the NIHR Oxford Biomedical Research Centre.

Find out more about our research below

Doctor looking at skin

Higher testosterone levels in men linked to greater melanoma risk

New research from Dr Eleanor Watts at the Nuffield Department of Population Health has found this association for the first time

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.

Novel imaging device enters first round of development funding programme

Anna Vella is designing CAPULET: a device to increase the accuracy in delivering particle beam radiotherapy in cancer treatment

Oxford spin out influencing patient care world wide

Oxford cancer research spin our Optellum has received FDA clearance for the world’s first AI-powered clinical decision support for early lung cancer diagnosis

Funding to improve childhood, teenage and young adult cancer detection

Dr Defne Saatci and Professor Julia Hippisley-Cox will develop risk prediction tools using the QResearch database to support the earlier detection of childhood, teenage and young adult cancer

New partnership enables access to state-of-the-art radiotherapy machine

University of Oxford, OUH and GenesisCare have partnered to provide access to a new ViewRay MRIdian machine. It is the first of its kind in the UK and will help to improve challenging cancer treatment through faster, tailored radiotherapy.

Drinking alcohol regularly increases cancer risk in Chinese populations

New research from the Nuffield Department of Population Health shows that reducing alcohol consumption in China could be an important cancer prevention strategy

New Oxford technology assesses cancer patient vulnerability to COVID-19

New research from Prof Julia Hippisley-Cox has resulted in thousands of cancer patients being given prioritised access to the COVID-19 vaccine.

Finding extracellular vesicle biomarkers for oesophageal cancer early detection

Prof Deborah Goberdhan’s lab is investigating extracellular vesicles and the proteins they express as potential biomarkers for the progression from Barrett’s Oesophagus to oesophageal cancer